Sai Life Sciences Releases Sustainability Report 2024–25

HYDERABAD, India, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s fastest-growing , today announced the release of its . Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 and the Sustainability Accounting Standards Board (SASB) standards, this sixth edition is presented under the theme “Driving climate action, deepening stakeholder trust.” The full report can be accessed .

Commenting on the release, Krishna Kanumuri, MD & CEO, Sai Life Sciences, said: “Reliability with responsibility is central to the CRDMO mandate and deeply embedded in how we operate at Sai Life Sciences. Over the past year, we translated this commitment into action through progress across climate actions, circular economy initiatives, people-led HR transformation, and tech-enabled innovation. Going forward, we are focused on scaling these efforts to build a resilient, science-forward, and sustainability-led operating model that delivers enduring value to our partners and stakeholders.”

The report outlines how the company’s sustainability strategy is anchored in nine strategic pillars that collectively guide its approach to responsible growth. These elements span water stewardship, climate action, circularity, biodiversity, sustainable procurement, human capital, governance and ethics, community engagement, and customer co-creation. Together, they constitute a cohesive framework that embeds sustainability priorities into every stage of the company’s operations. By aligning these elements with business objectives and stakeholder expectations, Sai Life Sciences positions sustainability as an intrinsic part of how it innovates, collaborates, and delivers impact.

During the year, the company advanced its internally defined Sustainable Development Goals (SDGs), which outline a clear roadmap for meeting its sustainability commitments by March 31, 2027. The report highlights ongoing progress in greenhouse gas reduction, a significant increase in renewable energy usage—with 96% of the API manufacturing unit in Bidar powered by renewables—and reductions in specific water consumption across facilities. It also documents significant community impact, with the company surpassing its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities. Strengthening its people agenda, the organisation saw steady growth in diversity, with women representing 14% of the workforce.

The 2024–25 Sustainability Report reflects the company’s long-term view—one that places science, responsibility, and collaboration at the centre of its growth ambition. As Sai Life Sciences continues to expand its global footprint, sustainability remains both a compass and a catalyst for shaping resilient, future-ready operations.

About Sai Life Sciences

Sai Life Sciences is a full-service Contract Research, Development & Manufacturing Organization (CRDMO) working with innovator pharma and biotech companies globally to accelerate the discovery, development, and commercialization of small molecules and emerging modalities. The company’s vision is “to advance the frontiers of science with our partners, delivering solutions that bring innovative medicines to patients worldwide.” With operations across India, the UK, and the US, Sai Life Sciences offers deep scientific expertise, world-class infrastructure, and a culture of excellence focused on quality, safety, and sustainability. For more details visit:

A photo accompanying this announcement is available at